Analyst consensus rating
Protagonist Therapeutics Analyst Rating: Strong Buy
Direct answer
Protagonist Therapeutics's consensus rating is Strong Buy.
14 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $182.36.
Forecast evidence checked November 12, 2026.
Get free Protagonist Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $134.86
- Average price target
- $182.36
- High price target
- $225.00
- Low price target
- $151.00
- Low target gap
- +12%
- Target upside
- +35.2%
- High target gap
- +66.8%
- Target range width
- 54.9%
- Consensus rating
- Strong Buy
- Analysts
- 14
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Protagonist Therapeutics?
Protagonist Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $182.36.
How far are Protagonist Therapeutics's low and high targets from the recorded price?
The low target implies +12%, while the high target implies +66.8%.
How many analysts are included in Protagonist Therapeutics's consensus?
The verified consensus includes 14 analysts.
How is Protagonist Therapeutics's target upside or downside calculated?
The average target of $182.36 is divided by the recorded price of $134.86, then one is subtracted to produce +35.2%. This does not guarantee a future return.
When was Protagonist Therapeutics's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.